<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Sophiris Bio, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Sophiris Bio, Inc.

    Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $80,700,000
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Randall E. Woods
    • FOUNDED
      2002
    • EMPLOYEES
      0-10
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Marinus Pharmaceuticals, Inc.

    Marinus Pharmaceuticals, Inc.

    Marinus Pharmaceuticals, Inc. is committed to improving the lives of patients suff...

    Marinus Pharmaceuticals, Inc. is committed to i...

    Filing Type:    PU
    Sonova Holding AG

    Sonova Holding AG

    Sonova, headquartered in Stäfa, Switzerland, is a leading provider of innovative h...

    Sonova, headquartered in Stäfa, Switzerland, is...

    Filing Type:    PU
    Akari Therapeutics Plc

    Akari Therapeutics Plc

    Akari is a biopharmaceutical company focused on developing inhibitors of acute and...

    Akari is a biopharmaceutical company focused on...

    Filing Type:    PU
    Venomyx, Inc

    Venomyx, Inc

    We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...

    We're developing Vipax, the world's first porta...

    Amount Raised:    $290,122.00
    Fundraising Status:    EC
    Filing Type:    CF
    Eloxx Pharmaceuticals, Inc.

    Eloxx Pharmaceuticals, Inc.

    Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developi...

    Eloxx Pharmaceuticals, Inc. is a clinical-stage...

    Filing Type:    PU
    Simulations Plus, Inc.

    Simulations Plus, Inc.

    Simulations Plus, Inc. is the leading developer of Absorption, Distribution, Metab...

    Simulations Plus, Inc. is the leading developer...

    Filing Type:    PU
    Trevi Therapeutics, Inc.

    Trevi Therapeutics, Inc.

    We are developing nalbuphine ER to treat serious neurologically mediated condition...

    We are developing nalbuphine ER to treat seriou...

    Filing Type:    PU
    Cassava Sciences, Inc.

    Cassava Sciences, Inc.

    The mission of Cassava Sciences is to detect and treat neurodegenerative diseases,...

    The mission of Cassava Sciences is to detect an...

    Filing Type:    PU
    Neurotez Inc.

    Neurotez Inc.

    We have used biochemical, molecular & cell biology and in vivo models to screen, i...

    We have used biochemical, molecular & cell biol...

    Amount Raised:    $7,656.00
    Fundraising Status:    EC
    Filing Type:    CF
    ©2025 National Investor Network. All Rights Reserved.